Abstract
Although the mu opioid receptor is the primary target of marketed opioid analgesics, several studies suggest the advantageous effect of combinations of mu and delta opioids. The novel compound RWJ-394674 [N,N-diethyl-4-[(8-phenethyl-8-azabicyclo]3.2.1]oct-3-ylidene)-phenylmethyl]-benzamide]; bound with high affinity to the delta opioid receptor (0.2 nM) and with weaker affinity to the mu opioid receptor (72 nM). 5′-O-(3-[35S]-thio)triphosphate binding assay demonstrated its delta agonist function. Surprisingly given this pharmacologic profile, RWJ-394674 exhibited potent oral antinociception (ED50 = 10.5 μmol/kg or 5 mg/kg) in the mouse hot-plate (48°C) test and produced a moderate Straub tail. Antagonist studies in the more stringent 55°C hot-plate test demonstrated the antinociception produced by RWJ-394674 to be sensitive to the nonselective opioid antagonist naloxone as well as to the delta- and mu-selective antagonists, naltrindole and β-funaltrexamine, respectively. In vitro studies demonstrated that RWJ-394674 was metabolized by hepatic microsomes to its N-desethyl analog, RWJ-413216 [N-ethyl-4-[(8-phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)-phenylmethyl]-benzamide], which, in contrast to RWJ-394674, had a high affinity for the mu rather than the delta opioid receptor and was an agonist at both. Pharmacokinetic studies in the rat revealed that oral administration of RWJ-394674 rapidly gave rise to detectable plasma levels of RWJ-413216, which reached levels equivalent to those of RWJ-394674 by 1 h. RWJ-413216 itself demonstrated a potent oral antinociceptive effect. Thus, RWJ-394674 is a delta opioid receptor agonist that appears to augment its antinociceptive effect through biotransformation to a novel mu opioid receptor-selective agonist.
Footnotes
-
doi:10.1124/jpet.106.104208.
-
ABBREVIATIONS: BW373U86, (±)-4-[(R*)-[(2S*,5R*)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-hydroxyphenyl)methyl]-N,N-diethylbenzamide hydrochloride; M1, N-desethyl-RWJ-394674; SNC-80, (+)-4-[(R)-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide); DAMGO, [d-Ala2,Nme-Phe4,Gly-ol5]-enkephalin; DPDPE, [d-Pen2,d-Pen5]-enkephalin; [35S]GTPγS, 5′-O-(3-[35S]thio)triphosphate; βFNA, β-funaltrexamine; DOR, delta opioid receptor; MPE, maximum possible effect; MS, mass spectrometry; MS/MS, tandem mass spectrometry; TAN-67, (4aS*,12aR*)-4a-(3-hydroxyphenyl)-2-methyl-1,2,3,4,4a,5,12,12a-octahydropyrido[3,4-b]acridine; i.v., intravenous; s.c., subcutaneous; i.p., intraperitoneal; SB219825, (-)-(4aS,8aR)-trans-2-[diethylamino)carbonyl]-6-ethyl-8a-(3-hydroxphenyl)-3-methyl-4,4a, 5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline; AR-M390, N,N-diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide; RWJ-394674, N,N-diethyl-4-[(8-phenethyl-8-azabicyclo]3.2.1]oct-3-ylidene)-phenylmethyl]-benzamide; RWJ-413216, N-ethyl-4-[(8-phenthyl-8-azabicyclo[3.2.1]oct-3-ylidene)-phenylmethyl]-benzamide.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|